Colon and Rectal Surgery Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Langenbecks Arch Surg. 2023 Sep 19;408(1):365. doi: 10.1007/s00423-023-03094-x.
Although not considered standard therapy, neoadjuvant chemotherapy (NAC) is an encouraging alternative for selected patients with locally advanced colon cancer (LAC). The aim of this study was to compare 30-day postoperative outcomes between patients undergoing upfront surgery and those undergoing NAC for LAC.
Using the ACS-NSQIP data from 2016 to 2020, 11,498 patients with LAC were divided into those who underwent upfront colectomy (96.2%) and those who received NAC (3.8%). The primary outcome was a composite outcome encompassing 30-day major postoperative complications. Propensity score matched (PSM) analysis and multivariable logistic regression were performed.
After PSM analysis, there was no statistically significant difference in the development of a major complication. NAC was not significantly associated with the primary outcome. Risk factors for postoperative complications were T4 stage, older age, male sex, black race, smoking, dependent status, severe COPD, hypoalbuminemia, and preoperative transfusion. Laparoscopic and robotic surgery was protective.
NAC did not increase the odds of developing a major complication.
尽管新辅助化疗(NAC)不被认为是标准疗法,但对于某些局部晚期结肠癌(LAC)患者来说,它是一种很有前途的替代方案。本研究旨在比较接受初始手术和接受 NAC 治疗的 LAC 患者的 30 天术后结局。
利用 2016 年至 2020 年 ACS-NSQIP 数据,将 11498 例 LAC 患者分为接受初始结肠切除术(96.2%)和接受 NAC 治疗的患者(3.8%)。主要结局是包括 30 天主要术后并发症的复合结局。进行倾向评分匹配(PSM)分析和多变量逻辑回归分析。
在 PSM 分析后,主要并发症的发生没有统计学上的显著差异。NAC 与主要结局无显著相关性。术后并发症的危险因素包括 T4 期、年龄较大、男性、黑种人、吸烟、依赖状态、严重 COPD、低白蛋白血症和术前输血。腹腔镜和机器人手术具有保护作用。
NAC 不会增加发生重大并发症的几率。